tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

DOW · Q3 2025 Earnings

Dow Inc.

Reported October 23, 2025

30-second summary

Dow delivered Q3 operating EBITDA of $868M, $68M above the ~$800M guide it set last quarter, with the cost program ($400M FY target) doing the heavy lifting. But the forward picture deteriorated: Q4 EBITDA guided to ~$725M (-16% QoQ), Alberta path-to-zero has been pushed off the agenda until January at the earliest, and CapEx is being cut $1B this year with another potential $2.5B reduction signaled for 2026. Management's framing has hardened from "lower-for-longer" to active capacity rationalization — Dow is now shutting three European assets and explicitly waiting on industry-wide supply destruction.

Headline numbers

EPS

Q3 FY2025

$-0.19

Revenue

Q3 FY2025

$9.97B

-8.0% YoY

Gross margin

Q3 FY2025

7.3%

Free cash flow

Q3 FY2025

$0.57B

Operating margin

Q3 FY2025

1.8%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$9.97B-8.0%$10.10B-1.3%
EPS$-0.19$-0.42+54.8%
Gross margin7.3%5.8%+154bps
Operating margin1.8%-0.2%+201bps
Free cash flow$0.57B$-1.13B+150.0%

Guidance

Dow reaffirmed FY2025 cost savings at ~$400M and raised near-term cash support target to >$6.5B, while guiding Q4 EBITDA to ~$725M (below Q3's $868M), reflecting normal seasonality, a $25M fire-related hit, and segment-specific headwinds.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Operating EBITDAQ3 FY2025approximately $800 million$868 million+$68 million above guideMet
Packaging & Specialty Plastics sequential EBITDAQ3 FY2025approximately $95 million higher than Q2sequentially higherwithin expected rangeMet
Industrial Intermediates & Infrastructure sequential EBITDAQ3 FY2025approximately $85 million higher than Q2sequentially higherwithin expected rangeMet
Performance Materials & Coatings sequential EBITDAQ3 FY2025approximately $65 million lower than Q2sequentially lowerwithin expected rangeMet

New guidance

MetricPeriodGuideYoY
Fourth Quarter EBITDAQ4 FY2025approximately $725 million
CapEx spending reductionFY 2025$1 billion reduction this year
Poly 6 polyethylene unit Q4 impactQ4 FY2025$25 million unfavorable impact for Q4
Working capital cash release (H2 2025)FY 2025$200 to $300 million in second half of year

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Near-term cash support actions (through 2026)
FY 2025
more than $6 billion by 2026more than $6.5 billion+$0.5B upward revisionLowered

Reaffirmed unchanged this quarter: Cost reduction program savings (FY2025) (approximately $400 million)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Packaging & Specialty Plastics$4.891B-11.0%
Industrial Intermediates & Infrastructure$2.834B-4.3%
Performance Materials & Coatings$2.082B-6.0%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
U.S. & Canada$3.914B-5.7%
EMEAI$3.09B-13.4%
Asia Pacific$1.838B-2.8%
Latin America$1.131B-11.1%
Operating EBIT$180 million
Operating EBITDA$868 million
Cash from Operating Activities$1,130 million
Volume Change YoY-1%
Local Price Change YoY-8%
Operating EBIT Margin1.8%
Cash Flow Conversion130.2%
Dividends Returned to Shareholders$249 million

Management tone

Q2 lower-for-longer admission → Q3 active capacity destruction and growth-project deferral

Last quarter management abandoned the cyclical-recovery framing; this quarter they moved from acknowledgment to action. The defining shift is the explicit deferral of Alberta path-to-zero, the project that was Dow's growth story for the last three years. Management's line — "our expectations for when this capacity will be needed have changed, given the prolonged down cycle our industry is facing" — concedes that the recovery timeline used to justify Alberta's economics no longer holds. The decision on timing is now deferred to the January Q4 call, which in practice means another quarter of doubt and another $2.5B of potential 2026 CapEx hanging on the answer.

The industry-rationalization narrative has shifted from "China needs to self-correct" to "we are doing it ourselves." Q2 management was calling for "aggressive industry response and regulatory action" on Chinese overcapacity. This quarter Dow announced "significant rationalization of global ethylene, propylene oxide, and siloxane capacities" via three European asset shutdowns. Management is no longer waiting for the cycle to fix itself — they are accelerating the supply destruction that a recovery requires, which is a tacit admission that external resolution isn't coming.

CapEx discipline has hardened from a $2.5B FY plan to active $1B cuts this year, with another $2.5B reduction flagged for 2026. "If we continued the way we are, you could see another $2.5 billion next year" is the kind of forward CapEx language a company uses when it is preparing the market for a defensive capital posture, not a growth one. The original $3.5B plan is gone.

Visibility language deteriorated further. Q2 management said they lacked "a clear line of sight to a recovery"; this quarter the framing is "the macroeconomic dynamics that I described continue to limit visibility into customer buying patterns, making projections challenging." That's an explicit confidence reduction in forecasting ability — and it sits underneath a Q4 guide that walks down 16% sequentially. The two go together.

Finally, the Poly 6 fire is being absorbed without much rhetorical defense — $25M Q4 hit, offline for the remainder of the year. In a normal cycle that disclosure would warrant more cushioning. Here it gets folded into a list of headwinds alongside seasonality and segment declines, suggesting management is calibrating investors to expect more operational noise as the company runs harder on cost.

Recurring themes management leaned on this quarter:

Near-term cash preservation through asset sales and cost reductionsIndustry-wide capacity rationalization as path to recoveryPositioning for market recovery with low-cost asset footprintManaging through prolonged down cycle with strategic actionsWorking capital optimization and dividend maintenanceTariff and trade policy uncertainty as key near-term headwind

Risks management surfaced:

Prolonged down cycle in chemicals industry with extended recovery timelineChina domestic market weakness and government lack of housing supportTrade and tariff uncertainty impacting customer investment decisions and purchasing patternsFeedstock cost volatility (natural gas, ethane) compressing marginsEuropean market potential continued contraction requiring further capacity rationalization

Answers to last quarter's watch list

Q3 operating EBITDA vs ~$800M guide and P&SP sequential lift — Beat: $868M actual, $68M above guide. P&SP segment EBITDA delivered the sequential improvement consistent with the ~$95M guidance. Cost program ($400M FY) was the primary driver, explicitly called out by management.
Resolved positively
Local price trajectory — Worsened: Q2 -7% YoY → Q3 -8% YoY. The pricing pressure didn't narrow despite tactical positives like record September volumes; redirected Chinese exports continue to weigh on EMEAI (-13.4% revenue YoY this quarter, deteriorating from -8.4% in Q2).
Resolved negatively
Free cash flow after the dividend cut — Resolved positively for FCF, but the underlying gap remains. FCF swung from -$1.13B to +$566M, helped by $1,130M cash from operations, the dividend cut (now $249M quarterly vs $496M prior), and the $200–300M H2 working capital release. The cut closed more of the gap than the Q2 framing suggested it would.
Resolved positively
SIDARA JV refinancing progress — Not addressed in this quarter's disclosed materials. The company didn't call it out on the print.
Continue monitoring
Pace of the $6B+ near-term cash support program — Materially advanced: target raised to >$6.5B (+$0.5B) and management stated "over half already achieved." This is the clearest positive operational data point of the quarter.
Resolved positively
Alberta path-to-zero FID timing — Indefinite deferral. Management explicitly said expectations for when the capacity will be needed "have changed" and pushed any decision to the January Q4 call. This confirms the Q2 read that the internal recovery assumption was slipping.
Resolved negatively

What to watch into next quarter

Whether Q4 operating EBITDA actually lands near ~$725M, and how much of the ~$143M sequential decline is one-off (Poly 6 $25M) vs structural — particularly whether PM&C's guided -$100M QoQ proves to be a floor or a continuing trend

The Alberta decision in January: full cancellation, multi-year deferral, or scope reduction. Anything short of a clear go-decision implies the additional $2.5B 2026 CapEx cut becomes base case

Local price trajectory: -7% → -8% over two quarters. Watch whether Q4 prints -9% or worse, which would signal the European asset shutdowns aren't yet tightening supply enough to stabilize pricing

Pace of remaining >$6.5B cash support program. "Over half achieved" implies roughly $3.0–3.3B still to come; watch for asset monetization timing (Diamond Infrastructure, NOVA judgment proceeds) and whether the new $0.5B raise is backed by identified actions or aspirational

Whether the $400M FY2025 cost target gets raised to keep the $1B-by-2026 run-rate plausible, given the deteriorating top line

EMEAI revenue trajectory after the three European asset shutdowns are announced — does -13.4% improve in Q4, or does demand fall faster than supply

Sources

  1. Dow Inc. Q3 2025 earnings press release and financial schedules, filed with the SEC: https://www.sec.gov/Archives/edgar/data/1751788/000175178825000153/exhibit991enrschedules3q25.htm
  2. Dow Inc. Q3 2025 earnings call CEO/CFO commentary (Jim Fitterling and Jeff Tate prepared remarks, as cited in extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.